Beranda › Penyakit Hati Steatotik › Maryland
Uji klinis Penyakit Hati Steatotik di Maryland
8 studi untuk Penyakit Hati Steatotik mencari peserta di lokasi di Maryland.
Kota di Maryland
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Mercy Medical Center - Baltimore, Baltimore
- Capital Digestive Care - Chevy Chase, Chevy Chase
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Baltimore
- Akero Clinical Study Site, Bethesda
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Mid-Atlantic GI Research, Greenbelt
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07288138Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT03884075Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
- National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 21 hingga 65 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT04781322A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Baltimore
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Jul 2026 · NCT06920043Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.